World's Best Scientists 2026 revealed!

D-Index & Metrics

Biology and Biochemistry

D-Index
63
Citations
20180
World Ranking
10020
National Ranking
4387

Overview

Peggy Scherle is affiliated with Incyte in the United States. Their research predominantly spans the fields of Biochemistry, Genetics and Molecular Biology, and Medicine, with significant focus on Molecular Biology, Oncology, Pathology and Forensic Medicine, Genetics, and Hematology as subfields.

The scientist's work extensively covers several key topics including cancer-related gene regulation, protein degradation and inhibitors, chromatin remodeling and cancer, cancer mechanisms and therapy, peptidase inhibition and analysis, CAR-T cell therapy research, and chronic lymphocytic leukemia research.

Among notable recent papers associated with Peggy Scherle are the following:

  • INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor models, 2020, published in PLoS ONE
  • A human CD137×PD-L1 bispecific antibody promotes anti-tumor immunity via context-dependent T cell costimulation and checkpoint blockade, 2021, published in Nature Communications
  • PRMT5 Inhibition Modulates E2F1 Methylation and Gene-Regulatory Networks Leading to Therapeutic Efficacy in JAK2V617F-Mutant MPN, 2020, published in Cancer Discovery
  • Targeting MYCN-expressing triple-negative breast cancer with BET and MEK inhibitors, 2020, published in Science Translational Medicine
  • Discovery of Pemigatinib: A Potent and Selective Fibroblast Growth Factor Receptor (FGFR) Inhibitor, 2021, published in Journal of Medicinal Chemistry

Frequent co-authors of Peggy Scherle include Kris Vaddi, Neha Bhagwat, Robert A. Baiocchi, Andrew P. Combs, and Lapo Alinari. Collaborative works with these colleagues range in publication count from 16 to 47.

Publications by the scientist appear primarily in venues such as Cancer Research, Blood, Molecular Cancer Therapeutics, Blood Advances, and PLoS ONE, reflecting the focus on cancer biology and hematology.

Best Publications

  • IDENTIFICATION OF A NOVEL INHIBITOR OF MITOGEN-ACTIVATED PROTEIN KINASE KINASE

    Margaret F. Favata;Kurumi Y. Horiuchi;Elizabeth J. Manos;Andrea J. Daulerio

  • Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms.

    Alfonso Quintás-Cardama;Kris Vaddi;Phillip Liu;Taghi Manshouri

  • Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8 + T cells directly within the tumor microenvironment

    Stefani Spranger;Holly K Koblish;Brendan Horton;Peggy A Scherle

  • Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity

    Xiangdong Liu;Niu Shin;Holly K. Koblish;Gengjie Yang

  • Selective Inhibition of JAK1 and JAK2 Is Efficacious in Rodent Models of Arthritis: Preclinical Characterization of INCB028050

    Jordan S. Fridman;Peggy A. Scherle;Robert Collins;Timothy C. Burn

  • MEK inhibitors: the chemistry and biological activity of U0126, its analogs, and cyclization products.

    John V. Duncia;Joseph B. Santella;C.Anne Higley;William J. Pitts

  • Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer

    Bin Bing S Zhou;Michael Peyton;Biao He;Changnian Liu

  • Inhibition of Mitogen-Activated Protein Kinase Kinase Blocks T Cell Proliferation But Does Not Induce or Prevent Anergy

    Dimuthu R. DeSilva;Elizabeth A. Jones;Margaret F. Favata;Bruce D. Jaffee

  • CCL2 mediates cross-talk between cancer cells and stromal fibroblasts that regulates breast cancer stem cells

    Akihiro Tsuyada;Amy Chow;Jun Wu;George Somlo

  • Inhibition of MAP kinase kinase prevents cytokine and prostaglandin E2 production in lipopolysaccharide-stimulated monocytes.

    Peggy A. Scherle;Elizabeth A. Jones;Margaret F. Favata;Andrea J. Daulerio

  • Hydroxyamidine Inhibitors of Indoleamine-2,3-dioxygenase Potently Suppress Systemic Tryptophan Catabolism and the Growth of IDO-Expressing Tumors

    Holly K. Koblish;Michael J. Hansbury;Kevin J. Bowman;Gengjie Yang

  • Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors

    Alexander J. Muller;Peggy A. Scherle

  • First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies.

    Gregory L. Beatty;Peter J. O'Dwyer;Jason Clark;Jack G. Shi

  • Discovery of potent competitive inhibitors of indoleamine 2,3-dioxygenase with in vivo pharmacodynamic activity and efficacy in a mouse melanoma model.

    Eddy W. Yue;Brent Douty;Brian Wayland;Michael Bower

  • INCB24360 (Epacadostat), a Highly Potent and Selective Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitor for Immuno-oncology

    Eddy W. Yue;Richard Sparks;Padmaja Polam;Dilip Modi

  • Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia

    Alireza Eghtedar;Srdan Verstovsek;Zeev Estrov;Jan Burger

  • Indoleamine 2,3-Dioxygenase and Its Therapeutic Inhibition in Cancer.

    George C. Prendergast;George C. Prendergast;William Paul Malachowski;Arpita Mondal;Peggy Scherle

  • Ly-GDI, a GDP-dissociation inhibitor of the RhoA GTP-binding protein, is expressed preferentially in lymphocytes

    Peggy Scherle;Timothy Behrens;Louis M. Staudt

  • Discovery and pharmacological characterization of a novel rodent-active CCR2 antagonist, INCB3344.

    Carrie M. Brodmerkel;Reid Huber;Maryanne Covington;Sharon Diamond

  • Identification of ADAM10 as a major source of HER2 ectodomain sheddase activity in HER2 overexpressing breast cancer cells.

    Phillip C.C. Liu;Xiangdong Liu;Yanlong Li;Maryanne Covington

Frequent Co-Authors

Robert C. Newton
Robert C. Newton Incyte (United States)
James M. Trzaskos
James M. Trzaskos Bristol-Myers Squibb (Germany)
William V. Williams
William V. Williams GlaxoSmithKline (United Kingdom)
Srdan Verstovsek
Srdan Verstovsek The University of Texas MD Anderson Cancer Center
Jennifer A. Pietenpol
Jennifer A. Pietenpol Vanderbilt University Medical Center
Selina Chen-Kiang
Selina Chen-Kiang Cornell University
Thomas F. Gajewski
Thomas F. Gajewski University of Chicago
Taha Merghoub
Taha Merghoub Cornell University
Jihye Paik
Jihye Paik Cornell University
Robert A. Copeland
Robert A. Copeland Accent Therapeutics (United States)

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Expanding your expertise in Biology and Biochemistry can open doors to a diverse range of career paths, many of which can now be pursued through online education. For those seeking advanced health specializations, there are accredited online dnp programs without dissertation requirements, making them more accessible to working professionals.

Leadership-oriented students may be interested in online doctoral programs healthcare administration, which prepare graduates for management and policy roles in hospitals, biotech firms, and research institutions.

Those passionate about pharmacy but without a prior pharmacy degree can explore online pharmd programs for non pharmacists, specifically designed to broaden professional opportunities in pharmaceutical sciences.

Additionally, if your interests intersect with sports, health, or wellness, pursuing an exercise science and nutrition degree online can prepare you for roles in fitness, nutrition counseling, or performance research.

With the flexibility of online learning, career advancement in these interconnected fields is more accessible than ever.

Best Scientists Citing Peggy Scherle

Trending Scientists

Recently Published Articles